Having trouble viewing this email? View in your browser.
Weekly News
28 September 2021

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.

ESCMID Online Education Course – Applications of MALDI-TOF Mass-Spectrometry in Clinical Microbiology

ESCMID is proud to announce that the Online Education Course ‘Applications of MALDI-TOF Mass-Spectrometry in Clinical Microbiology’ is open for registration.

Don’t miss this online workshop which will include immersive video demonstrations alongside talks from experts in the field of MALDI-TOF Mass spectrometry.

See the programme flyer and register on the ESCMID Online Courses website.

Open call to join the ESCMID Scientific Affairs Subcommittee

ESCMID is pleased to announce an open call for a member to join the Scientific Affairs Subcommittee, within the theme of Epidemiology, Public Health and Vaccinology. ESCMID members interested in joining the subcommittee can find the full call document here. The deadline to apply is 20 Oct, 2021.

TAE Steering Committee nominations – Closing soon!

ESCMID is collecting nominations for two new TAE Steering Committee (TAE SC) members, one member with a background in Clinical Microbiology (CM) and one with a background in Infectious Diseases (ID). The nomination phase closes on 7 Oct, 2021 at 12:00 noon CEST.

IDWeek Presents: 24 Hours of COVID -19 - Chasing the Sun

ESCMID is very proud to participate in the IDWeek event Chasing the Sun: COVID-19, Beyond the Horizon. This global event will begin tomorrow, Wednesday, 29 Sept, 2021, and conclude on Thursday, 30 Sept, 2021. This event is offered free of charge.

Public Consultation Phase open for new ESCMID Guidelines

"ESCMID COVID-19 Living Guidelines: Drug treatment and clinical management" is undergoing public consultation. Check here to participate. The deadline to provide feedback and comments is 7 Oct, 2021.

Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection

This study examined changes in seroprevalence HCWs and the protective effect of antibodies against SARS-CoV-2. They found seropositivity against SARS-CoV-2 persisted for at least six months in the vast majority of HCWs and was associated with a significantly lower risk of reinfection.